Clinical trials: Pioglitazone
Major Depressive Disorder, Insulin Resistance
Pioglitazone in Patients With Mood Disorders
The purpose of this study is to see how an insulin sensitizing medication, Pioglitazone, can cause changes in mood in some depressed patients. Study participants receive assessment of their cognitive and metabolic functioning.
- Trial name
- NCT01559857
- Testing
- Pioglitazone, Sugar Pill
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Stanford University
Fatty Liver
Insulin Resistance in Non-alcoholic Fatty Liver Disease
The study is designed to investigate the relationship between insulin resistance and non-alcoholic fatty liver disease (NAFLD) and to investigate potential mechanisms underlying insulin resistance in NAFLD by determining…
- Trial name
- NCT01289639
- Testing
- fenofibrate, pioglitazone
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Cardiovascular Diseases
Efficacy Study of Pioglitazone and Atorvastatin Combination Therapy in Treating Subjects With Elevated Risk for Cardiovascular Disease
The purpose of this study is to determine the effect of pioglitazone, once daily (QD), and atorvastatin combination therapy compared to atorvastatin monotherapy in patients at risk for cardiovascular disease.
- Trial name
- NCT00770575
- Testing
- Pioglitazone and atorvastatin, Atorvastatin
- Volunteers
- 148 people
- Sponsor
- Takeda
Alcohol Use Disorder
Effects of Pioglitazone on Stress Reactivity and Alcohol Craving
The purpose of this study is to examine the effects of pioglitazone on stress-induced relapse risk in a laboratory model and to examine the effects of pioglitazone on drinking, stress/anxiety, and alcohol craving in the natural…
- Trial name
- NCT05107765
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- The University of Texas Health Science Center, Houston
Type 2 Diabetes
Clinical Trial of Pioglitazone Treatment in Patients With Type 2 Diabetes Mellitus and Covid-19
The treatment with pioglitazone added to the standard treatment of patients with DM2 hospitalized for COVID-19 may produce a decrease in the number of patients who progress to a second phase of severe systemic inflammation.
- Trial name
- NCT04535700
- Testing
- Pioglitazone 30 mg, standard of care
- Where
- Spain
- Volunteers
- 8 people
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Diabetes Mellitus, Type 2
Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus
This phase IV study is a prospective open-label multi-center study to investigate the effect of a temporary individualized poly-pharmaceutical De-escalation treatment with the target to regenerate ß-cell function over 12 weeks on…
- Trial name
- NCT04027023
- Testing
- Diabetes mellitus Type 2 De-escalation treatment (DET)
- Where
- 2 sites in United States, Germany
- Volunteers
- 9 people
- Sponsor
- Sciema UG
Chronic Kidney Diseases
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
Chronic kidney disease (CKD) is associated with a higher risk of cardiovascular disease and death. An overactive sympathetic nervous system in CKD patients is one of the major mechanisms increasing the cardiovascular risks in…
- Trial name
- NCT03471117
- Testing
- Pioglitazone
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- The University of Texas at Arlington
Myocardial Reperfusion Injury
The Role of Pioglitazone in Vascular Transcriptional Remodeling
Acute myocardial infarction (AMI) remains the leading cause of death worldwide. In this scenario, early coronary reperfusion is the main therapeutic strategy as it substantially reduces mortality.
- Trial name
- PREVALENT (NCT05775380)
- Testing
- Pioglitazone 45 mg
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- University of Campinas, Brazil
Healthy
Bioequivalence Study of Torrent Pharmaceuticals Ltd's Pioglitazone Hydrochloride Tablets Under Fasting Conditions
Objective: subjects to compare the single dose bioavailability of Torrent's Pioglitazone Hydrochloride Tablets 1 × 45 mg and Actos® Tablets 1 × 45 mg of Takeda Pharmaceuticals America, Inc.
- Trial name
- NCT01797666
- Testing
- Torrent's Pioglitazone Hydrochloride Tablets 45 mg
- Where
- India
- Volunteers
- healthy volunteers welcome
- Sponsor
- Torrent Pharmaceuticals Limited
Diabetes Mellitus, Type 2
Targeting Beta-cell Failure in Lean Patients With Type 2 Diabetes
The majority of people with type 2 diabetes (T2D) are overweight, and while weight gain is a major contributor to diabetes, a minority of patients with T2D are not overweight or obese.
- Trial name
- Lean-DM (NCT04657939)
- Testing
- Liraglutide, Pioglitazone
- Where
- United Kingdom
- Volunteers
- 57 people
- Sponsor
- University of Leeds
Type 2 Diabetes
Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5 mg and Pioglitazone 30 mg
A randomized, open-label, multiple dosing, three-way crossover clinical trial to investigate the pharmacokinetic/pharmacodynamic drug-drug interaction of evogliptin 5 mg and pioglitazone 30 mg after oral administration in healthy…
- Trial name
- NCT02753803
- Testing
- Evogliptin, Pioglitazone, Evogliptin+Pioglitazone, Pioglitazone, Evogliptin, Evogliptin+Pioglitazone, Evogliptin, Evogliptin+Pioglitazone, Pioglitazone
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Dong-A ST Co., Ltd.
Diabetes Mellitus, Type 2
Medication in Early Diabetes (MED) Study
This study compares metformin (current first-line medication) to pioglitazone (a newer diabetic medication currently approved for combination use).
- Trial name
- NCT00437970
- Testing
- Pioglitazone, Metformin
- Where
- Australia
- Volunteers
- healthy volunteers welcome
- Sponsor
- Menzies School of Health Research
Pulmonary Hypertension, Pulmonary Hypertension Due to Lung Diseases
Bioenergetic Effect of Pioglitazone in CLD-PH
The goal of this clinical trial is to learn about the safety and efficacy of Pioglitazone in people with Pulmonary Hypertension (PH) due to Chronic Lung Disease (CLD).
- Trial name
- NCT06336798
- Testing
- Pioglitazone 30mg, Labs
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Emory University
Type 2 Diabetes Mellitus
Study of Rivoglitazone in Type 2 Diabetes Mellitus
This is a 26-week study in subjects with type 2 diabetes currently sub-optimally controlled by diet and exercise or with non-thiazolidinedione antihyperglycemic monotherapy.
- Trial name
- NCT00484198
- Testing
- Pioglitazone, Rivoglitazone
- Where
- 183 sites in United States, Argentina and 16 more
- Volunteers
- 1,912 people
- Sponsor
- Daiichi Sankyo
Diabetes Mellitus, Type 2
Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM
The objective of the current study is to investigate the safety and tolerability of BI 1356 (5 mg / once daily) given for 78 weeks in different modalities of treatment.
- Trial name
- NCT00736099
- Testing
- linagliptine 5 mg, linagliptine 5 mg and pioglitazone 30 mg
- Where
- 232 sites in United States, Argentina and 30 more
- Volunteers
- 2,122 people
- Sponsor
- Boehringer Ingelheim
Arterial Occlusive Disease, Intermittent Claudication
ARREST PAD (Peripheral Arterial Disease)
This trial will test the hypothesis that inflammation and insulin resistance contribute to reduced walking distance in subjects with intermittent claudication by impairing vascular reactivity and skeletal muscle metabolic…
- Conditions
- Arterial Occlusive Disease, Intermittent Claudication, Insulin Resistance
- Trial name
- NCT00153166
- Testing
- atorvastatin and pioglitazone
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Diabetes Mellitus, Type 2
Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone
This study is designed to evaluate, in a primary care setting, the safety and efficacy of vildaglipgtin as add on therapy to metformin relative to TZD added to metformin in patients with type 2 diabetes inadequately controlled by…
- Trial name
- NCT00396227
- Testing
- vildagliptin, thiazolidinedione (TZD)
- Where
- United States
- Volunteers
- 2,665 people
- Sponsor
- Novartis Pharmaceuticals
Liver Fibrosis
Transplantation of Autologous Mesenchymal Stem Cell in Decompensate Cirrhotic Patients With Pioglitazone
Liver cirrhosis (LC) is the final destiny in chronic liver disease. Liver transplantation is the only effective therapy available to these patients.
- Trial name
- NCT01454336
- Testing
- Cell injection
- Where
- Iran
- Volunteers
- 3 people
- Sponsor
- Royan Institute
Lung Cancer, NSCLC
Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s)
Lung cancer is one of the most common and serious types of cancer. Lung tumor cells exploit immune checkpoint proteins (ICPs) to maintain immune tolerance and thus promote tumor progression and invasion.
- Trial name
- NCT06502249
- Where
- Egypt
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
T2DM, MAFLD
The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients With T2DM Complicated With MAFLD
To compare the efficacy and safety of the combination of alogliptin and actoplus met with that of actoplus met alone in improving the glucose and lipid metabolism and pancreatic function in T2DM patients complicated with MAFLD.
- Trial name
- NCT07289750
- Testing
- alogliptin and actoplus met, actoplus met
- Volunteers
- 80 people
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine